354 related articles for article (PubMed ID: 20931348)
1. Are the current IHS guidelines for migraine drug trials being followed?
Hougaard A; Tfelt-Hansen P
J Headache Pain; 2010 Dec; 11(6):457-68. PubMed ID: 20931348
[TBL] [Abstract][Full Text] [Related]
2. Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults.
Deen M; Martinelli D; Pijpers J; Diener HC; Silberstein S; Ferrari MD; Ashina M; Tassorelli C; Yuan H
Cephalalgia; 2019 Jul; 39(8):1058-1066. PubMed ID: 31042062
[TBL] [Abstract][Full Text] [Related]
3. Have the IHS
Alpuente A; Tassorelli C; Diener HC; Silberstein SD; Pozo-Rosich P
Cephalalgia; 2020 Jul; 40(8):778-787. PubMed ID: 32056459
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults.
Silberstein S; Tfelt-Hansen P; Dodick DW; Limmroth V; Lipton RB; Pascual J; Wang SJ;
Cephalalgia; 2008 May; 28(5):484-95. PubMed ID: 18294250
[TBL] [Abstract][Full Text] [Related]
5. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
6. General lack of use of placebo in prophylactic, randomised, controlled trials in adult migraine. A systematic review.
Hougaard A; Tfelt-Hansen P
Cephalalgia; 2016 Sep; 36(10):960-9. PubMed ID: 26553731
[TBL] [Abstract][Full Text] [Related]
7. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.
Oskoui M; Pringsheim T; Billinghurst L; Potrebic S; Gersz EM; Gloss D; Holler-Managan Y; Leininger E; Licking N; Mack K; Powers SW; Sowell M; Victorio MC; Yonker M; Zanitsch H; Hershey AD
Neurology; 2019 Sep; 93(11):500-509. PubMed ID: 31413170
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the reporting of adverse events in controlled clinical trials conducted in 2010-2015 on migraine drug treatments.
Tfelt-Hansen P; Lindqvist JK; Do TP
Cephalalgia; 2018 Oct; 38(12):1885-1895. PubMed ID: 29448820
[TBL] [Abstract][Full Text] [Related]
9. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators.
Tfelt-Hansen P; Pascual J; Ramadan N; Dahlöf C; D'Amico D; Diener HC; Hansen JM; Lanteri-Minet M; Loder E; McCrory D; Plancade S; Schwedt T;
Cephalalgia; 2012 Jan; 32(1):6-38. PubMed ID: 22384463
[No Abstract] [Full Text] [Related]
10. Migraine prophylactic drugs: proof of efficacy, utilization and cost.
Ramadan NM; Schultz LL; Gilkey SJ
Cephalalgia; 1997 Apr; 17(2):73-80. PubMed ID: 9137841
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
12. Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.
Oskoui M; Pringsheim T; Holler-Managan Y; Potrebic S; Billinghurst L; Gloss D; Hershey AD; Licking N; Sowell M; Victorio MC; Gersz EM; Leininger E; Zanitsch H; Yonker M; Mack K
Neurology; 2019 Sep; 93(11):487-499. PubMed ID: 31413171
[TBL] [Abstract][Full Text] [Related]
13. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition.
Abu-Arafeh I; Hershey AD; Diener HC; Tassorelli C;
Cephalalgia; 2019 Jun; 39(7):803-816. PubMed ID: 30947525
[TBL] [Abstract][Full Text] [Related]
14. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings.
Orr SL; Aubé M; Becker WJ; Davenport WJ; Dilli E; Dodick D; Giammarco R; Gladstone J; Leroux E; Pim H; Dickinson G; Christie SN
Cephalalgia; 2015 Mar; 35(3):271-84. PubMed ID: 24875925
[TBL] [Abstract][Full Text] [Related]
15. American Headache Society members' assessment of headache diagnostic criteria.
Nash JM; Lipchik GL; Holroyd KA; McCool H; Stensland M;
Headache; 2003 Jan; 43(1):2-13. PubMed ID: 12864752
[TBL] [Abstract][Full Text] [Related]
16. WITHDRAWN: Eletriptan for acute migraine.
Smith LA; Oldman AD; McQuay HJ; Moore RA
Cochrane Database Syst Rev; 2007 Jul; 2001(1):CD003224. PubMed ID: 17636718
[TBL] [Abstract][Full Text] [Related]
17. Eletriptan for acute migraine.
Smith LA; Oldman AD; McQuay HJ; Moore RA
Cochrane Database Syst Rev; 2001; (3):CD003224. PubMed ID: 11687056
[TBL] [Abstract][Full Text] [Related]
18. Do ED patients with migraine headaches meet internationally accepted criteria?
Fiesseler FW; Kec R; Mandell M; Eskin B; Anannab M; Riggs RL; Richman PB
Am J Emerg Med; 2002 Nov; 20(7):618-23. PubMed ID: 12442241
[TBL] [Abstract][Full Text] [Related]
19. Italian guidelines for primary headaches: 2012 revised version.
Sarchielli P; Granella F; Prudenzano MP; Pini LA; Guidetti V; Bono G; Pinessi L; Alessandri M; Antonaci F; Fanciullacci M; Ferrari A; Guazzelli M; Nappi G; Sances G; Sandrini G; Savi L; Tassorelli C; Zanchin G
J Headache Pain; 2012 May; 13 Suppl 2(Suppl 2):S31-70. PubMed ID: 22581120
[TBL] [Abstract][Full Text] [Related]
20. Drugs for preventing migraine headaches in children.
Victor S; Ryan SW
Cochrane Database Syst Rev; 2003; (4):CD002761. PubMed ID: 14583952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
